PFIZER Nutrition has signed a
three-year license agreement with
Jennewein Biotechnologie to
develop and market two human
milk oligosaccharides (HMOs).
Primarily the HMO products will
focus on boosting the functional
and immunological benefits of
infant formulas, as HMOs are a
major component in breast milk.
“The cooperation between Pfizer
Nutrition and Jennewein
Biotechnologie will accelerate the
developments in this field by
bringing together specific
complementary competencies,”
said Dr. Stefan Jennewein,
Jennewein Biotechnologie.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Aug 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Aug 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.